


RealRate

MEDICINAL PRODUCTS 2020

IMMUCELL CORP DE Rank 10 of 52





ImmuCell



MEDICINAL PRODUCTS 2020

RealRate

The relative strengths and weaknesses of IMMUCELL CORP DE are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of IMMUCELL CORP DE compared to the market average is the variable Property, Plant and Equipment, Net, increasing the Economic Capital Ratio by 53% points. The greatest weakness of IMMUCELL CORP DE is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 23% points.

The company's Economic Capital Ratio, given in the ranking table, is 96%, being 101% points above the market average of -4.3%.

Input Variable	Value in 1000 USD
Assets, Current	13,189
Assets, Non-Current	27
General and Administrative Expense	10,989
Goodwill	210
Liabilities, Current	2,495
Liabilities, Non-Current	7,205
Other Assets	0
Other Compr. Net Income	-74
Other Expenses	342
Other Liabilities	0
Other Net Income	0
Other Revenues	13,723
Property, Plant and Equipment, Net	25,266
Research and Development	3,688

Output Variable	Value in 1000 USD
Liabilities	9,701
Assets	38,692
Expenses	15,018
Revenues	13,723
Stockholders Equity	28,991
Net Income	-1,296
Comprehensive Net Income	-1,333
Economic Capital Ratio	96%

